title: Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.
abstract: In malignancies where no universally expressed dominant Ag exists, the use of tumor cell-based vaccines has been proposed. We have modified a mouse neuroblastoma cell line to express either CD80 (B7.1), CD137L (4-1BBL), or both receptors on the tumor cell surface. Vaccines expressing both induce a strong T cell response that is unique in that among responding CD8 T cells, a T effector memory cell (T(EM)) response arises in which a large number of the T(EM) express the alpha-chain of VLA-2, CD49b. We demonstrate using both in vitro and in vivo assays that the CD49b(+) CD8 T cell population is a far more potent antitumor effector cell population than nonfractionated CD8 or CD49b(-) CD8 T cells and that CD49b on vaccine-induced CD8 T cells mediates invasion of a collagen matrix. In in vivo rechallenge studies, CD49b(+) T cells no longer expanded, indicating that CD49b T(EM) expansion is restricted to the initial response to vaccine. To demonstrate a mechanistic link between the expression of costimulatory molecules on the vaccine and CD49b on responding T cells, we stimulated naive T cells in vitro with artificial APC expressing different combinations of anti-CD3, anti-CD28, and CD137L. Although some mRNA encoding CD49b was induced by combining anti-CD3 with anti-CD28 or CD137L, the highest level was induced when all three signals were present. This indicates that CD49b expression results from additive costimulation and that the level of CD49b message serves as an indicator of the effectiveness of T cell activation by a cell-based vaccine.
authors.affiliation: Department of Pediatrics, Section of Hematology-Oncology, Medical College of Wisconsin Milwaukee, WI 53226, USA.
authors.forename: Xiaocai
authors.initials: X
authors.lastname: Yan
authors.forename: Bryon D
authors.initials: BD
authors.lastname: Johnson
authors.forename: Rimas J
authors.initials: RJ
authors.lastname: Orentas
mesh_terms: D053330:4-1BB Ligand / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D002454:Cell Differentiation / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018920:Coculture Techniques; D006801:Humans; D016219:Immunotherapy, Adoptive; D039421:Integrin alpha2 / Q000096:biosynthesis* / Q000235:genetics; D020014:K562 Cells; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008805:Mice, Inbred A; D009447:Neuroblastoma / Q000378:metabolism / Q000517:prevention & control*; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000378:metabolism
chemical_list: D053330:4-1BB Ligand; D019496:Cancer Vaccines; D039421:Integrin alpha2; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9
references.citation: N Engl J Med. 1999 Oct 14;341(16):1165-73
references.pmid: 10519894
references.citation: J Biol Chem. 1985 Dec 5;260(28):15246-52
references.pmid: 2415516
references.citation: Blood. 2000 Mar 1;95(5):1804-9
references.pmid: 10688841
references.citation: J Biol Chem. 2000 Mar 17;275(11):8255-61
references.pmid: 10713152
references.citation: J Clin Invest. 2000 Mar;105(6):721-9
references.pmid: 10727440
references.citation: J Immunol. 2000 Nov 1;165(9):4935-40
references.pmid: 11046019
references.citation: J Immunol. 2001 Mar 1;166(5):3484-90
references.pmid: 11207307
references.citation: J Biol Chem. 2001 Jun 29;276(26):23518-24
references.pmid: 11313353
references.citation: Eur J Immunol. 2001 May;31(5):1523-30
references.pmid: 11465109
references.citation: J Immunol. 2001 Aug 1;167(3):1313-24
references.pmid: 11466348
references.citation: Cell Immunol. 2001 May 25;210(1):56-65
references.pmid: 11485353
references.citation: J Clin Invest. 2002 Mar;109(5):651-9
references.pmid: 11877473
references.citation: J Immunol. 2002 Oct 15;169(8):4230-6
references.pmid: 12370353
references.citation: J Pediatr Hematol Oncol. 2003 Jan;25(1):8-13
references.pmid: 12544767
references.citation: Cell Immunol. 2003 Mar;222(1):15-26
references.pmid: 12798304
references.citation: Bone Marrow Transplant. 2003 Jul;32(1):103-6
references.pmid: 12815485
references.citation: Eur J Immunol. 2003 Aug;33(8):2133-41
references.pmid: 12884287
references.citation: J Immunol. 2003 Sep 15;171(6):2804-11
references.pmid: 12960301
references.citation: Blood. 2004 Jan 1;103(1):177-84
references.pmid: 12969968
references.citation: Blood. 2004 Mar 15;103(6):2214-20
references.pmid: 14645004
references.citation: Blood. 2004 May 1;103(9):3396-402
references.pmid: 14739220
references.citation: Immunology. 2004 May;112(1):105-16
references.pmid: 15096190
references.citation: J Cell Biol. 1989 Nov;109(5):2455-62
references.pmid: 2530239
references.citation: Proc Natl Acad Sci U S A. 1989 Dec;86(24):9906-10
references.pmid: 2557634
references.citation: Science. 1991 Mar 29;251(5001):1600-2
references.pmid: 2011740
references.citation: Eur J Immunol. 1992 Dec;22(12):3111-9
references.pmid: 1446704
references.citation: Eur J Biochem. 1993 Jul 1;215(1):151-9
references.pmid: 8344274
references.citation: Blood. 2003 Mar 1;101(5):1718-26
references.pmid: 12406881
references.citation: J Biol Chem. 1994 Jan 7;269(1):463-9
references.pmid: 8276836
references.citation: Eur J Immunol. 1994 Sep;24(9):2000-5
references.pmid: 7522156
references.citation: Blood. 1995 Oct 15;86(8):3006-14
references.pmid: 7579393
references.citation: Annu Rev Biochem. 1995;64:403-34
references.pmid: 7574488
references.citation: Eur J Immunol. 1998 Mar;28(3):1116-21
references.pmid: 9541607
references.citation: J Exp Med. 1998 Jun 1;187(11):1849-62
references.pmid: 9607925
references.citation: J Cell Physiol. 1998 Sep;176(3):634-41
references.pmid: 9699516
references.citation: Blood. 1998 Sep 15;92(6):1941-9
references.pmid: 9731051
references.citation: Cell Immunol. 1999 Feb 25;192(1):13-23
references.pmid: 10066342
references.citation: J Immunol. 1999 May 1;162(9):5037-40
references.pmid: 10227968
references.citation: J Immunol. 1999 May 15;162(10):5917-23
references.pmid: 10229828
references.citation: Ann N Y Acad Sci. 2004 Dec;1028:69-80
references.pmid: 15650233
references.citation: J Immunol. 2005 Feb 15;174(4):1898-905
references.pmid: 15699116
references.citation: J Immunother. 2005 Sep-Oct;28(5):449-60
references.pmid: 16113601
references.citation: Eur J Immunol. 2005 Dec;35(12):3673-82
references.pmid: 16304637
references.citation: Inflamm Bowel Dis. 2006 Mar;12(3):172-7
references.pmid: 16534417
references.citation: J Immunol. 2006 Jun 15;176(12):7511-24
references.pmid: 16751398
references.citation: J Immunol. 2006 Jul 15;177(2):968-75
references.pmid: 16818752
references.citation: J Immunother. 2007 Feb-Mar;30(2):203-14
references.pmid: 17471167
references.citation: J Immunother. 2007 Feb-Mar;30(2):227-33
references.pmid: 17471169
references.citation: Lancet. 2007 Jun 23;369(9579):2106-20
references.pmid: 17586306
references.citation: J Immunol. 2007 Oct 1;179(7):4910-8
references.pmid: 17878391
references.citation: J Immunol. 2000 Feb 15;164(4):2009-15
references.pmid: 10657652